Life-saving new cancer drugs are being held back so the Government can save money, claims GlaxoSmithKline chief executive

The head of Britain's biggest drugs company has accused the Government of systematically delaying the introduction of new cancer drugs in order to save money.

GlaxoSmithKline chief executive Sir Andrew Witty warned that ministers were making false economies as they tried to grapple with the deficit in the public finances.

In an interview with the BBC, he said that governments across Europe had already cut drug prices by 5 per cent a year - costing GSK around £300 million per annum.      More Read